Basel Medical Group Ltd Ordinary Shares (BMGL)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable businesses with honest financials and a margin of safety. Basel Medical Group is an $11.3 million market-cap healthcare provider in Singapore with 82 employees, offering orthopedic, trauma, sports medicine, spine, foot/ankle, neurosurgical, and general practice services. That is a real operating business, but the numbers I have do not show a moat. At the 2026-10-13 close of $3.85, FairStock calculates a P/B of 1.23 and a P/E of -0.67, meaning the company is not earning a profit. FairStock's return metrics show ROE of -147.37% and ROCE of -15.46%, while debt-to-equity is 1.51. A FairStock Piotroski F-Score of 1/9 and an Altman Z-Score of 0.42 point to serious financial weakness, not a fortress balance sheet. Revenue and profit growth are not available, and there is only 0 year of filed results, so I cannot judge a multi-year track record. The Lynch category is none because at least three years of filed results are needed. The 52-week range of $0.38 to $10.60 shows extreme volatility for a microcap. Graham would ask what the assets are worth and whether earnings are stable; here book value is being marked at a premium while returns on equity and capital are deeply negative. Buffett would ask whether the niche orthopedic practice has pricing power and repeat demand; the figures alone do not prove it. Until I see filed revenue, net income, cash flow, and lower leverage, this looks speculative. The price is not a clear bargain; the business must first show it can earn money. FairStock Score 37/100 supports caution.

In plain English: Basel Medical Group provides healthcare services in Singapore, with a focus on bone, joint, spine, sports medicine and brain surgery services. The business looks financially weak right now: it is losing money, carries a lot of debt compared with its equity, and has almost no filed financial history to judge it by. At $3.85, the price does not look clearly cheap against those numbers, and the risk is high.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer